For demonstrating how a nonprofit can develop drugs as well as Big Pharma can, Mel Spigelman ’70, CEO of TB Alliance, is one of Fast Company’s “Most Creative People in Business for 2020.” TB Alliance’s pretomanid became one of three new anti-tuberculosis drugs approved by the FDA and the first developed and registered by a nonprofit. TB Alliance is partnering with major generic-drug makers to get pretomanid to market.
See more notes:
Class of 1970